Ceva Group

We are France's leading animal health company, headquartered in Libourne.

With more than 7,000 employees located in 47 countries, Ceva strives daily to bring to life its vision as a One Health company: “Together, beyond animal health”. To us, this expresses that the health and wellbeing of people, animals, and our planet are deeply interconnected.

Our 21 R&D centers and 32 production sites worldwide attest to our commitment to research and the development of increasingly innovative solutions.

In 1999, two French pharmaceutical companies, Sanofi and Synthélabo, merged to form Sanofi-Synthélabo. Soon afterwards the new company divested its animal health and nutrition business. This business was acquired through a leveraged management buyout. This resulted in the establishment of Ceva Santé Animale with its headquarters in Libourne, near Bordeaux, France.

In 2007, Ceva management and employees became majority shareholders in the company’s third financing round.

-------

Ceva inherited a rich history of vaccine development and manufacturing through its European subsidiary, Ceva Phylaxia. Founded in Hungary in 1912, the Phylaxia Vaccine Production Cie produced the first vaccine against classical swine fever. World famous scientists including József Marek and Aladár Aujeszky were closely associated with the company.

Over time we have become a truly global research-based business and a recognised leader and pioneer in areas as diverse as hatchery vaccination, reproductive management of farm animals and behavioural control products for dogs and cats.

This growth has been achieved both organically and through carefully chosen strategic acquisitions of companies from all around the world.

Since 1999, we have evolved into the world's fifth-largest animal health company, as well as the leading animal health company in France.

We are an independent company, majority-owned by our employees.

Starting in 2007, the company has been supported by long-term, carefully selected, financial partners who share their values, vision and sense of purpose.

In 2025, Ceva strengthened its position in the animal health sector through a strategic capital restructuring that balanced management independence with new investment opportunities. 

The company’s innovative approach attracted a diverse range of investors, combining loyal “Friends of Ceva“ partners with prominent global investment firms. This carefully crafted shareholding structure not only demonstrates investor confidence in Ceva’s future but also reinforces the company’s dedication to advancing animal health solutions and environmental sustainability.

These partners’ trust and support are essential for Ceva to achieve its growth objectives and ensure the company’s independent future in the long term.